Experts Recommend Bharat Biotech’s Covaxin For Phase 2/3 Trials On 2-18-Year-Olds
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
Outlook Web Bureau 12 May 2021, Last Updated at 10:51 am PTI Outlook Web Bureau 2021-05-12T07:48:31+05:30 Experts Recommend Bharat Biotech’s Covaxin For Phase 2/3 Trials On 2-18-Year-Olds outlookindia.com 2021-05-12T10:51:25+05:30
Also read
An expert panel on Tuesday recommended Bharat Biotech’s Covid-19 vaccine Covaxin for phase II/III clinical trial on those aged between two to 18 years, official sources said.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and im
Loading the player. Outright lies : China on reports that its military scientists probed weaponising COVID-19 in 2015
China on Monday termed as outright lies , the media reports that its military scientists investigated weaponising coronaviruses five years before the COVID-19 pandemic outbreak and said it is an attempt by the US to smear the country. The US State Department reportedly obtained the bombshell documents, which were written by Chinese military scientists and senior public health officials in 2015 as part of their own investigation into the origins of COVID-19.
PM Modi cancels G-7 summit visit in June over COVID-19 situation
Prime Minister Narendra Modi will not travel to the UK to attend the G-7 summit in June due to the coronavirus situation in the country. The Prime Minister was slated to be a special invitee to the summit in Cornwall at UK Prime Minister Boris Johnson s invitation. The summit was scheduled for June 11-13.
Covaxin set for clinical trials on children aged between 2 and 18 years
Covaxin set for clinical trials on children aged between 2 and 18 years
The trial will take place in 525 subjects at various sites, including AIIMS Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences, Nagpur.
Share
Updated: May 12, 2021, 12:06 PM IST
In a breakthrough, an expert panel recommended Bharat Biotech was on Tuesday to send its COVID-19 vaccine ‘Covaxin’ for phase II and phase III clinical trials on children between the ages of two and 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur, officials said.
URL copied Image Source : PTI
Bharat Biotech s Covaxin recommended by expert panel for phase 2/3 trials on 2-18 year-olds
Bharat Biotech s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.
1938 Children play on an empty street during COVID-induced lockdown in Lucknow on May 1, 2021. PTI/file
New Delhi, May 11
Bharat Biotech s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said.
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.